pleomorphic xanthoastrocytoma
Information
- Disease name
- pleomorphic xanthoastrocytoma
- Disease ID
- DOID:4852
- Description
- "A low grade glioma that is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies." [url:https\://www.cancer.gov/rare-brain-spine-tumor/tumors/pleomorphic-xanthroastrocytoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes | Mutation | Description | Source | Links |
---|
NCT ID | Status | Phase | Summary | Start date | Completion date |
---|---|---|---|---|---|
NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
NCT03900689 | Completed | Social Determinants of Health in Glioblastoma Population | May 22, 2019 | March 27, 2022 | |
NCT04065776 | Recruiting | N/A | Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma | August 28, 2019 | July 2028 |
NCT04541082 | Recruiting | Phase 1 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | October 26, 2020 | February 2025 |
NCT05180825 | Recruiting | Phase 2 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | May 5, 2022 | December 1, 2031 |
NCT03975829 | Recruiting | Phase 4 | Pediatric Long-Term Follow-up and Rollover Study | November 4, 2019 | May 29, 2026 |
NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
- Disase is a (Disease Ontology)
- DOID:0080829
- Cross Reference ID (Disease Ontology)
- ICDO:9424/3
- Cross Reference ID (Disease Ontology)
- NCI:C4323
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:189924002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0334586
- Exact Synonym (Disease Ontology)
- Pleomorphic Xantho-astrocytoma